If there are some unknown variables that are influencing the stock's price, surely shareholders would have some concerns. The stock's movement is disjointed with the company's earnings growth, which ideally should move in the same direction. The fact that shareholders are sitting on a loss on the value of their shares in the past few years is certainly disconcerting. So shareholders would probably want the company to be less generous with CEO compensation. Since shareholders would have lost about 22% over three years, some Natus Medical Incorporated investors would surely be feeling negative emotions. Has Natus Medical Incorporated Been A Good Investment? Historical performance can sometimes be a good indicator on what's coming up next but if you want to peer into the company's future you might be interested in this free visualization of analyst forecasts. The lack of revenue growth isn't ideal, but it is the bottom line that counts most in business. Shareholders would be glad to know that the company has improved itself over the last few years. Furthermore, Jonathan Kennedy directly owns US$5.3m worth of shares in the company, implying that they are deeply invested in the company's success. So it looks like Natus Medical compensates Jonathan Kennedy in line with the median for the industry. In comparison with other companies in the industry with market capitalizations ranging from US$400m to US$1.6b, the reported median CEO total compensation was US$3.1m. We think total compensation is more important but our data shows that the CEO salary is lower, at US$689k. Notably, that's an increase of 14% over the year before. We think shareholders might be reluctant to increase compensation for the CEO at the moment, according to our analysis below.Ĭheck out our latest analysis for Natus Medical How Does Total Compensation For Jonathan Kennedy Compare With Other Companies In The Industry?Īccording to our data, Natus Medical Incorporated has a market capitalization of US$935m, and paid its CEO total annual compensation worth US$3.8m over the year to December 2020. They could also influence management through voting on resolutions such as executive remuneration. Shareholders may want to question the board on the future direction of the company at the upcoming AGM on 16 June 2021. What is concerning is that despite positive EPS growth, the share price has not tracked the trend in fundamentals. Shareholders of Natus Medical Incorporated ( NASDAQ:NTUS) will have been dismayed by the negative share price return over the last three years.
0 Comments
Leave a Reply. |